Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit.


Risultati immagini per Gastroparesis



A third of patients with Gp symptoms actively use cannabinoids for their chronic symptoms. Most of these patients perceive improvement in their symptoms with cannabinoids. Patients taking cannabinoids were younger and more symptomatic than those not taking cannabinoids. Further studies on the efficacy and safety of cannabinoids in Gp will be useful.


On Wednesday, February 13th, 2019, the European Union voted on and passed a resolution to further the efforts of medical cannabis legalization in the countries that make it up. The vote comes after the World Health Organization (WHO) recommended that cannabis be reclassified under the international treaties system to a less severe Schedule-1.


Though countries will not be required to adhere to the resolution’s language, its details are promising. According to Forbes, the resolution, “seeks to incentivize European nations to increase access to medical marijuana, prioritizing scientific research and clinical studies.”

While the European Union resolution suggests countries take steps to increase medical cannabis access and research, it does not actually change any countries laws. The main goal of the resolution is clearly to increase access to medical cannabis for research purposes, an idea many have argued in favor of. The resolution states that research should be conducted about, “the possible uses of THC, CBD and other cannabinoids for medical treatment, as well as their effects on the human body, including lessons drawn from the experience of off-label prescribing of cannabis.”

The influence of the World Health Organization on the European Union’s resolution regarding cannabis is clear. The resolution, “Stresses the importance of close cooperation and coordination with the World Health Organization (WHO) in connection with further EU steps in the field of medical cannabis.”



Europe features multiple countries with massive economies that lead the world in various industries. While some countries in the EU have more lax laws, cannabis has been considered illegal continent-wide since its outset. The new European Union medical cannabis resolution will help begin the process of making the EU and its member countries a force to be reckoned with in the cannabis industry.

At the moment, America and Canada are considered the leaders in terms of medical cannabis legalization. Cannabis is completely legal in Canada and more than 30 U.S. states have legalized the medicinal use of cannabis. To this point, the European Union has lagged behind those two countries in terms of both research and access to medical cannabis. With the passage of the new cannabis resolution, the European Union will now have a chance to catch up.


As the 2020-presidential election draws ever closer, potential candidates are making their positions on a number of issues public. Many Democrats are positioning themselves as ultra-progressive and most are open in their support of full cannabis legalization. In the last few days, California Senator Kamala Harris embraced and expanded on her full support of federal cannabis legalization.


In a recently released book, Harris expressed her support for federal cannabis legalization. She also admitted to smoking cannabis and “inhaling” when she was younger. In her new book, Harris wrote,

“We need to legalize marijuana and regulate it.” Harris continued by calling for, “…expunging nonviolent marijuana-related offenses from the records of the millions of people who have been arrested and incarcerated so they can get on with their lives.”

Kamala Devi Harris is an American attorney and politician who has served as the junior United States Senator from California since 2017. A member of the Democratic Party, she previously served as the 32nd Attorney General of California from 2011 to 2017, and as the 27th District Attorney of San Francisco from 2004 to 2011.

Kamala Devi Harris is an American attorney and politician who has served as the junior United States Senator from California since 2017. A member of the Democratic Party, she previously served as the 32nd Attorney General of California from 2011 to 2017, and as the 27th District Attorney of San Francisco from 2004 to 2011.
Those positions, while progressive and exciting for many cannabis consumers and members of the cannabis industry, have not always been what Harris believes in. During her tenure as San Francisco District Attorney in 2010, Harris was open in opposition to the legalization of cannabis in California. She told reporters,

“that drug selling harms communities.”
While hypocrisy regarding the legalization of cannabis is more rule than exception when it comes to American politicians, the fact that Harris has now shifted her views to align with those of the American people is optimistic to say the least.


The American electorate has rapidly evolving views. One thing that is becoming apparent is that they support the legalization of cannabis more than ever before. Gallup found that, “Sixty-six percent of Americans now support legalizing marijuana, another new high in the trend over nearly half a century. Gallup also found that surprisingly, a majority of Republicans now support the legalization of cannabis. With 53% of Republicans and 75% of Democrats now supporting legalization, it is clear that politicians must appeal to the masses and work to legalize cannabis use federally.

Kamala Harris is an early favorite for the Democratic nomination in a field of more than 20 possible candidates. She will continue to push a progressive agenda with policies like federal cannabis legalization and criminal justice reform at the forefront. For those who look to make cannabis a safe to use and non-criminal plant, Harris may be a solid option for the presidency.

The 9 States Most Likely To Legalize Marijuana In 2019

Risultati immagini per Mason Tvert,‘2019 could be a banner year for legalization via state legislatures,’ Mason Tvert, spokesman for the Marijuana Policy Project, said in an email. ‘Several states across multiple regions of the country are strongly considering ending prohibition and regulating marijuana for adult use. A growing number of state lawmakers and governors are either getting behind these…

Sorgente: The 9 States Most Likely To Legalize Marijuana In 2019

US Virgin Islands Enacts Medical Cannabis Access Law

Charlotte Amalie, Virgin Islands: Democratic Gov. Albert Bryan Jr. signed legislation into law last week establishing a regulated medical cannabis market in the US Virgin Islands.

Risultati immagini per Democratic Gov. Albert Bryan Jr.
Democratic Gov. Albert Bryan Jr.

The Medical Cannabis Patient Care Act permits qualified patients to possess and access cannabis and cannabis-infused products from licensed dispensaries. Specified patients will also be permitted to cultivate their own marijuana.

Under the law, regulators must finalize rules governing the program within 180 days.

The Virgin Islands is the third US territory to legalize medical cannabis access — joining Guam and Puerto Rico.

For more information, contact Justin Strekal, NORML Political Director, at (202) 483-5500.

Study: THC/CBD Extract Associated With Reduced Spasticity In ALS Patients

Milan, Italy: The daily administration of the proprietary cannabis extract nabiximols — a spray containing nearly equal ratios of plant-derived THC and CBD — reduces spasticity in patients with amyotrophic lateral sclerosis (ALS aka Lou Gehrig’s disease), according to clinical trial data published in the journal Lancet Neurology.

Italian researchers compared the administration of nabiximols versus placebo in a cohort of ALS patients over a period of six weeks. Researchers reported an improvement in spasticity scores among those patients randomly assigned nabiximols, while those provided the placebo experienced a deterioration in their scores. Authors determined that nabiximols treatment was “well tolerated” and that “no serious adverse events occurred” over the trial period.

They concluded: “In this proof-of-concept trial, nabiximols had a positive effect on spasticity symptoms in patients with motor neuron disease and had an acceptable safety and tolerability profile. These findings should be investigated further in larger clinical trials.”

Risultati immagini per NabiximolsNabiximols, also known under the brand name Sativex, is prescribed in numerous countries throughout the world in the treatment of multiple sclerosis.

Risultati immagini per NabiximolsFor more information, contact Paul Armentano, NORML Deputy Director, at: Full text of the study, “Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): A multicenter, double-blind, randomized, placebo-controlled, phase 2 trial,” appears in Lancet Neurology.

New Zealand Moves Forward with Cannabis Cultivation License

Published By Anthony Johnson on January 22, 2019

Just one month after New Zealand announced plans to potentially legalize recreational cannabis during the country’s general election in 2020, one company has been given a license to cultivate 16 strains of cannabis. This includes both CBD and THC strains of the plant.

The company, Hikurangi Cannabis Company, based in Ruatoria, just received an amendment to its license from the New Zealand Ministry of Health. Hikurangi had previously been issued a license last year to cultivate low THC varieties of cannabis after growing CBD since 2016.Risultati immagini per Hikurangi Cannabis Company

The company subsequently sourced high THC varieties of the plant that also passed New Zealand’s strict biosecurity laws about what kind of seeds and plants can be imported into the country. In doing so, Hikurangi has formed a partnership with researchers from Nepal and India to protect and commercialize so-called “landrace” strains of cannabis. They are also actively forming research partnerships with universities and commercial partners along the old “Silk Road” trade route from Afghanistan to Eastern Europe. Beyond Eurasia, the company is focused on building a network of indigenous communities in North and South America plus Africa to find new strains.

Landrace Strains Are Highly Prized Globally

Landrace cannabis strains are highly sought globally as they are considered the “natural,” non-hybridized forms of the plant. Adding landrace genetics to existing strains can add new kinds of effects (and even colors) to specially bred new “hybrid” varieties.

Hikurangi’s efforts to find such rare genetics is also intriguing from a historical perspective. Cannabis is believed to have originated in Asia and was spread west into Europe by an early nomadic tribe called the Scythians.

New Zealand’s Cannabis Law Expected To Be Community and Non-Commercially Managed

New Zealand’s foray into the commercial cannabis space is likely to be different from North American models of reform. According to a recent poll, 62% of Kiwis would prefer cannabis reform to be less commercial, including options such as home grow, not for profit community collectives, and larger grow spaces managed under the auspices of community trusts.

These ideas are not new of course. Spain’s Podemos party has already suggested that cannabis should become a source of nationally grown wealth rather than ceded to international interests. The Spanish industry so far has also, with a few noted exceptions, developed along a not-for-profit model. This is also a growing theme in Asia, but is likely to spread as the industry becomes more institutionalized globally.

The pilot study conducted by Massey University looked at different options for regulating commercial cannabis and found wide public frustration with the current system of regulating alcohol, which grants “Licensing Trusts,” a monopoly on the right to operate retail outlets and taverns.

If this also sounds familiar, the same fight is currently underway in Canada, which became the second country in the world to legalize the sale of recreational cannabis in October of 2018. Regulations regarding everything from provincial brick and mortar outlets to online sales are still in a state of flux. The future of New Zealand’s cannabis laws aren’t set, but there are certainly set to be very interesting.

To obtain the latest information on regulatory models across Europe, be sure to attend upcoming International Cannabis Business Conferences in Barcelona, Berlin, and Zurich. Before heading to Europe the ICBC will be returning to San Francisco, California, USA, for the fifth consecutive year on February 7-8. Vancouver, British Columbia, Canada is also on the 2019 agenda. Tickets for all ICBC events are on sale now


The wave of cannabis legalization in the United States of America continues to sweep from coast-to-coast.  During the 2018 midterm elections, Michigan legalized recreational cannabis use and two other states voted to legalize medicinal cannabis use. Now, New Jersey wants in on the fun. Committees from both the state Senate and state Assembly of New Jersey approved a bill that would legalize the recreational sales and use of cannabis. The bill will now be voted on by the entire Democratic controlled state Legislature. Should it pass, it would then either be signed into law or vetoed by Democratic governor Phil Murphy. Murphy promised during the New Jersey Governor’s race that he would legalize recreational cannabis during his time in office.



The recreational cannabis legalization bill, which was revealed to the public only last week, would legalize the possession and use of one ounce or less of marijuana for people at least 21 years old. According, the bill would also impose a 12 percent tax on the commercial marijuana industry in the state. An extra 2 percent excise tax could be raised for towns which host cannabis businesses.

The legalization bill would most importantly force the Administrative Office of the Courts to establish an electronic filing system for expedited expungements. Language within the bill states that this must occur within the first six months of the passage of the bill.

When commenting on whether or not he would support the bill in its current form, Gov. Murphy said, “It’s too early to tell,” elaborating that, “We haven’t commented on specifics, but I am very happy that this is moving [forward].”


Cannabis terapeutica, dopo Milano arriva l’appello del Piemonte

In Piemonte, nell’ultimo anno, è triplicato il numero di pazienti trattati con medicinali a base di cannabis e il numero delle prescrizioni è cresciuto di oltre cinque volte.

l’assessore regionale alla Sanità Antonio Saitta.

“I dati ci dicono che c’è una richiesta crescente da parte dei pazienti e c’è un aumento delle prescrizioni da parte dei medici di cannabis ad uso medico”, spiega in una nota l’assessore regionale alla Sanità Antonio Saitta.“Purtroppo non sempre lo Stabilimento chimico farmaceutico militare di Firenze, l’unico autorizzato per legge alla fornitura, riesce a soddisfare tempestivamente tutte le richieste. Chiediamo dunque al Ministero della Salute, secondo quanto prevede la norma, di individuare e autorizzare altri enti alla produzione dei farmaci”.

Un problema che si sta riscontrando un po’ ovunque, tanto che, per esempio, il consiglio comunale di Milano ha approvato una mozione che invita il Comune a prendere in considerazione la possibilità di avviare una coltivazione controllata di cannabis terapeutica nel Parco Sud e nelle tante cascine limitrofe alla città. Una scelta, come abbiamo già avuto modo di sottolineare, che avrebbe molteplici benefici: per i pazienti, che non avrebbero problemi di mancanza di scorte, e per il sistema Paese, che potrebbe favorire la crescita economica di un settore che offrirebbe molti sbocchi anche dal punto di vista dei posti di lavoro.
La cannabis ad uso medico, che in Piemonte è stata regolamentata con una legge approvata dal Consiglio regionale nel 2015, può essere impiegata per sei aree di patologie e soltanto quando le terapie tradizionali si sono rivelate inefficaci. A Torino e nelle altre province piemontesi, oltre il 70% dei trattamenti riguarda analgesia nel dolore cronico o neurogeno.

In dettaglio, nel corso del 2017 i malati trattati con cannabis ad uso terapeutico sono stati 639 (con un incremento rispetto al 2016 pari al 205,74%) per un totale di 2.683 prescrizioni. Di queste, 770 sono state effettuate da medici di medicina generale (28,70%) e 1.913 da medici specialisti (71,30%). Nel 2016 erano stati 209 per un totale di 483 prescrizioni.

La spesa totale registrata in Regione Piemonte nel 2017 per tali preparati è stata di 193.089 euro, con un incremento del 107,07% rispetto al 2016.